Perhaps one of the first indications that VIP related and it was suggested that they were perhaps might not be a hormone was obtained -from its derived from a common ancestral peptide. Further distribution in the gut. Unlike the other members of weight was added to these suggestions by the fact the secretin family, which are located in discrete that the many biological effects of VIP, which regions of the upper small intestine (secretin) and include systemic vasodilation, glycogenolysis (Kerins pancreas (glucagon) , VIP appeared to have a much and Said, 1973) , lipolysis (Frandsen and Moody, wider distribution. High concentrations of VIP were' 1973), inhibition of gastric acid production found throughout the length of the gut from the (Makhlouf and Said, 1975) , stimulation of oesophagus to the rectum, including the pancreas myocardial contractility , insulin (Bloom et al., 1975; Said, 1975) (Fig. 2) . A similar *Serum is [unsuitable for VIP estimations as the level falls distribution of VIP-producing endocrine cells was during the time taken for the clot to form and retract. also observed by some authors (Polak et al., 1974;  Plasma should be frozen immediately after collection-Ed. Buffa et al., 1977) (Fig. 2) . Others, however, (Larsson In classical endocrine theory, a hormone is produced from a discrete gland in response to a stimulus and is secreted into the circulatory system in which it is carried to a distant target organ where it exerts its effect. In normal subjects, VIP does circulate but only at very low concentrations circulation by other agents. Instillation of hydrochloric acid into the duodenum in sufficient quantity to stimulate the release of secretin also results in a significant increase in plasma VIP concentrations from a basal level of 1.7 to a peak at 6 minutes of 6*6 pmol/l, a rise which is sustained for at least 30 minutes (Ebeid et al., 1977a; Bloom et al., 1978) . Similarly, the intraduodenal administration of hypertonic saline (6 %, 3 %) and phenylamine in the dog also results in the release of VIP (Ebeid et al., 1977a ). An intravenous infusion of calcium gluceptate (Ebeid et al., 1977b) , and, in pigs, electrical stimulation of the vagus are other procedures which result in a considerable release of VIP (Schaffalitzky de Muckadell et al., 1977) . It is particularly interesting that in the latter much higher VIP concentrations were attained in portal blood than in systemic blood, perhaps confirming previous reports that the liver is one of the major sites of degradation of VIP. Similarly, in the pig, higher systemic levels are produced by an infusion of VIP into the systemic veins than when the same solution is infused into the portal vein (Fig. 3) . Degradation of VIP in the liver suggests that its actions may be limited to the gastrointestinal tract and portal circulation. Perhaps another indication that VIP does not have an important role as a peripheral circulatory hormone is its rapid clearance from plasma. The half life of porcine VIP has been reported as 0*85 minutes in the pig and 1 03 to 1 *22 minutes in man . This is far more rapid than that of the classical hormones gastrin, pancreatic glucagon, and secretin. litres daily) , hypokalaemia, and hypo-or achlorhydria had extremely high circulating VIP concentrations, often in excess of 300 pmol/1 (Fig. 4) . The known biological actions of this peptide fitted very well with a causative role of VIP for the symptoms of the disease. This finding was later confirmed by Said and Faloona (1975) . In many cases, the source of these high concentrations of VIP was a pancreatic tumour composed of VIP-containing endocrine-type cells (Fig. 4) . However, in a few cases (Fig. 4) the source of VIP was not an endocrine-like tumour but an abdominal ganglioneuroblastoma. This led to a search for the presence of VIP in a wide range of both animal and human tissue. High concentrations of VIP were found in the brains of the rat, cat, pig, and man (Bryant et al., 1976; Larsson et al., 1976b; Said and Rosenberg, 1976) and also in other organs such as the adrenals, urinary bladder, gallbladder, and salivary glands (Bryant et al., 1976) (Table 2, (Fig. 5 ). In the brain extract there was a small peak of VIP immunoreactivity of apparently higher molecular weight, but its significance is unknown. Immunofluorescent studies of human and animal intestine have demonstrated VIP in many tiny nerve fibres in the mucosa and muscle layers (Bryant et al., 1976) . Similarly, VIP-containing nerve fibres were Wharton et al., in preparation) . Within several months of the original demonstration of VIP in nervous tissues various independent groups using different antisera reported similar data. In 1977, Fuxe and co-workers showed by immunocytochemical techniques the presence of VIP in nerve terminals in the cerebral cortex, hypothalamus, amygdaloid nucleus, and corpus striatum. Giachetti and colleagues (1977) also demonstrated very elegantly by subcellular fractionation that in the cerebral cortex and hypothalamus the highest concentrations of VIP were in the synaptosome fraction.
Since the initial localisation of VIP in nerve fibres in the central nervous system, it has been found in the superior and inferior mesenteric ganglia (Hokfelt et al., 1977) , submucous and myenteric plexi of the intestinal wall (Bryant et al., 1976; Larsson et al., 1976b) , cerebral vascular nerves (Larsson et al., 1976a) , and nerves of the female and male genital organs (L. I. Larsson et al., unpublished observations) .
The very wide distribution of VIP in nervous tissue, its questionable presence in true endocrine cells, its wide spectrum of actions, and its rapid clearance time from the circulation thus differentiate this peptide from the other members of the secretin family and obviously challenge the original belief that VIP is a simple gastrointestinal hormone.
The nerve endings of the autonomic nervous system are classically divided into two types, adrenergic and cholinergic, each type containing small secretory granules. Recently, ultrastructural studies have indicated a system of nerve terminals within the gut with much larger, more electron dense granules resembling those of the peptidergic system of the neurohypophysis, and evidence exists that these consist, in part at least, of VIP-containing nerves (see contribution by Dr Polak, page 68). It is possible then that VIP may be acting as a neurotransmitter substance within this new division of the autonomic nervous system. Recently, it has been shown that very high concentrations of VIP occur in nerve fibres in the neurohypophysis so that it is possible that VIP might affect the release of vasopressin or-oxytocin and may have an osmoregulatory role (Van Noorden et al., 1979) .
In summary, VIP immunoreactivity has been demonstrated in association with nerves throughout the central nervous system. However, the evidence for a neurotransmitter role is still very circumstantial. An endocrine role cannot be excluded, as while it would seem likely that it does not play an important part in the regulation of the peripheral circulation, it might well act within the portal system or locally on blood vessels within the gut as a paracrine substance. Certainly, in the case of the Verner-Morrison syndrome, endocrine effects of VIP are apparent, but it must be stressed that this is a pathological situation.
Until it is shown that VIP is released in response to a stimulus at the presynaptic junction and elicits an action potential at the postsynaptic junction, and that this action can be blocked by application of specific antagonists, we can still only speculate as to the functional role of VIP.
